Caris Life Sciences is a leading AI-driven precision medicine company that transforms healthcare through comprehensive molecular profiling and advanced machine learning. The company specializes in analyzing cancer at the molecular level by performing whole exome and whole transcriptome sequencing on patient tissue and blood samples. Its flagship offerings include MI Profile for tissue-based profiling, Caris Assure for blood-based analysis, and Caris Detect, a multi-cancer early detection blood assay leveraging ultra-deep whole genome sequencing. Caris has built one of the world's largest multimodal clinico-genomic databases, combining genomic, transcriptomic, and proteomic data with clinical outcomes from over 740,000 matched patient records. The company serves oncologists and patients by providing molecular information to guide therapy selection, support drug development, and enable early disease detection. Founded in 2008 and headquartered in Irving, Texas, Caris operates internationally with offices across major medical and research hubs, delivering precision medicine solutions that help physicians and patients make informed treatment decisions based on individual tumor biology.